What researchers and institutions need to know before running a psychedelic study

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Academic researchers, research institutions, and biotech companies planning a psychedelic clinical study.

The short answer

Running a psychedelic study is a lawful way to work with these substances, but it requires clearing several federal and institutional gates before any participant is dosed. A study generally needs an FDA authorization to give an investigational drug to people, a DEA registration to handle a Schedule I substance, and approval from an institutional review board to protect the human subjects. The study drug has to come from an authorized source, and the institution and the state have their own requirements. These approvals take time and must be in place first. Research authorization covers the approved study; it is not permission to provide psychedelic services to the public outside the trial.

A lawful path, but a narrow and regulated one

Bona fide research is one of the few settings in which people can lawfully work with Schedule I psychedelics in the United States. That path is real, and it is how the clinical evidence on these substances is being built. It is also narrow. The authorization a study receives covers the specific protocol the regulators approved, for research purposes, under defined controls. It does not authorize treating patients outside the study or providing services to the public, a distinction covered in Clinical trials vs. legal access programs: what’s the difference?.

The federal approval to study the drug in people

To give an investigational drug to human participants in order to study its safety and effectiveness, a sponsor generally has to have an Investigational New Drug application in effect with the FDA. The IND sets out the protocol, the safety data, and the manufacturing information, and the FDA reviews it before the study can proceed. IND applications and FDA oversight of psychedelic clinical trials covers what the IND involves and how the FDA oversees the trial once it is underway.

IRB review and human-subjects protection

A study involving human participants must be reviewed and approved by an institutional review board before it begins. The board examines the protocol, the risks and benefits, and the informed-consent process to protect the people in the study. Psychedelic trials raise particular human-subjects questions because of the vulnerability of participants during dosing and the intensity of the experience. IRB review and human subjects protection in psychedelic research covers that review.

DEA Schedule I registration

Because psychedelics are Schedule I substances, the researcher and the institution need a DEA registration specific to Schedule I research before they can possess or handle the drug. This registration is separate from the FDA authorization and comes with its own application, security, and recordkeeping requirements. DEA Schedule I researcher registration: what it involves and how to get it covers that process.

Sourcing the study drug

A study cannot use just any material. The investigational drug has to come from an authorized, properly registered source and meet the quality standards the regulators expect, which generally means pharmaceutical-grade material produced under controlled conditions. Securing a supply from a licensed manufacturer or an established drug-supply program is part of setting up the study, and it has to be arranged in coordination with the FDA and DEA requirements.

Institutional, state, and funding requirements

Beyond the federal approvals, the research site has its own requirements: institutional sign-offs, controlled-substance handling and storage through the site’s pharmacy, security, and compliance review. Some states require their own controlled-substance research registration on top of the federal one. Funding adds its own conditions, and a federally funded study carries additional rules. These institutional and state layers sit alongside the federal approvals rather than replacing them.

The sequence and the timeline

The approvals build on one another and take time. A sponsor develops the protocol, assembles the safety and manufacturing information, files the IND, obtains the DEA registration, secures IRB approval, arranges the drug supply, and clears the institution’s own reviews, all before the first participant is enrolled. None of these is quick, and a study cannot shortcut them by starting and seeking approval afterward. Drug development timelines and what FDA approval actually requires covers how long the broader path runs.

When public information may be enough

The FDA, the DEA, and the federal human-subjects rules are all public, and a researcher can read them to understand the approvals a study requires and roughly what each involves. Professional and academic resources describe how psychedelic trials have been set up. Learning the structure is well supported by public sources; assembling a specific study is where specialized help comes in.

When you should speak with a lawyer

A research team planning a psychedelic study should bring in legal and regulatory expertise early, because the approvals are interlocking and a misstep in one can delay or derail the whole study. Counsel and regulatory professionals can help sequence the IND, the DEA registration, the IRB review, and the drug supply, and can keep the institution’s and the state’s requirements aligned. Getting the regulatory plan right at the start saves time that is hard to recover later. Why ‘promising research’ is not the same as lawful commercial availability covers the line between doing the research and offering the result to the public.

You might also want to read

This article provides general legal information, not legal advice, and does not create an attorney-client relationship. Psychedelic law differs by state and changes over time. Consult a licensed attorney in your jurisdiction before acting on anything described here.